Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HFpEF Clear all
Completed Phase 3 Interventional Results available

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

NCT03877224
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of CRD-740 in Heart Failure

NCT05409183
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
CRD-740, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

NCT05562063
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Entresto™ 49Mg-51 mg tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

NCT03756285
View directory record Official record
Conditions
Heart Failure
Interventions
AZD4831, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Jun 26, 2026, 6:03 AM EDT
Recruiting Phase 4 Interventional

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

NCT07263035
View directory record Official record
Conditions
Heart Failure, Heart Failure - NYHA II - IV, Heart Failure Acute, Acute Heart Failure (AHF)
Interventions
Furosemide intravenous solution
Drug
Lead sponsor
Lakeland Regional Health Systems, Inc.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT04600115
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT03254485
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
IW-1973, Placebo Oral Tablet
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
45 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

NCT02941705
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Diastolic
Interventions
Allogeneic Derived Cells, Placebo/Control Arm
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Dapagliflozin (DAPA) Effects in HFpEF

NCT04730947
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional Results available

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Oral treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jun 26, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371
View directory record Official record
Conditions
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

Inspiratory Muscle Training in HFpEF

NCT06510231
View directory record Official record
Conditions
Heart Failure
Interventions
Inspiratory Muscle Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT04546555
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
Device · Other
Lead sponsor
Daniel L Lustgarten
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 26, 2026, 6:03 AM EDT
Terminated Not applicable Interventional Results available

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

NCT03195660
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Interventions
ASV Therapy
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
San Diego, California • Philadelphia, Pennsylvania • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

NCT02145351
View directory record Official record
Conditions
Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
Interventions
Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Rheos System for the Treatment of HFpEF Heart Failure

NCT00957073
View directory record Official record
Conditions
Heart Failure
Interventions
Rheos® system
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
22
States / cities
Mobile, Alabama • Inglewood, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jun 26, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

NCT03448406
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 26, 2026, 6:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac Rehab Effects in HFpEF

NCT04506606
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Afferent block
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

NCT04998877
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 26, 2026, 6:03 AM EDT
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
View directory record Official record
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 26, 2026, 6:03 AM EDT